Clinical trials: Concentration
Attention Deficit Hyperactivity Disorder
Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)
The study is long-term extension study to evaluate long-term safety and efficacy of Atomoxetine in Japanese pediatric patients with Attention-Deficit/Hyperactivity Disorder (AD/HD).
- Trial name
- NCT00191386
- Testing
- Atomoxetine hydrochloride
- Where
- 24 sites in Japan
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with…
- Trial name
- NCT02633527
- Testing
- 100mg SPN-812, 200mg SPN-812, 300mg SPN-812
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention, Memory
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women
The purpose of this study is to investigate the effects of the dietary supplement oréVida™ (active ingredient on the basis of a culinary herb)administered twice daily in an acute study on an improvement in vigilance, attention…
- Conditions
- Attention, Memory, Alertness
- Trial name
- NCT01143194
- Testing
- oréVida™
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Sleep Apnea, Obstructive
Divided Attention Steering Simulator Alertness Test
Driving simulator programmes are used under a wide range of conditions, and a correlation of driving performance and real accident risks in patients with obstructive sleep apnoea syndrome(OSAS)could be shown.
- Trial name
- DASS (NCT01460173)
- Testing
- Divided Attention Steering Simulator (DASS)
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Atopic Dermatitis, Eczema
Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to ointment base (vehicle) in subjects with Atopic Dermatitis (AD).
- Trial name
- NCT01359787
- Testing
- Mapracorat, Vehicle without active
- Where
- Germany
- Volunteers
- 197 people
- Sponsor
- Bayer
Healthy Volunteers
Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects
This is an open-label, randomized, parallel design study to evaluate the PK comparability, safety, tolerability and immunogenicity of a single SC dose of 360 mg CC 93538 using two different drug concentrations, 180 mg/mL and 150…
- Trial name
- NCT04373187
- Testing
- CC-93538
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Celgene
Appearance of Facial Wrinkles, Aesthetic
Evaluation of a Non-cross-linked Hyaluronic Acid Medical Device ("Electri" and "XELA REDERM") for Improving Facial Skin Appearance
The goal of this clinical investigation is to learn whether injectable implants based on non-cross-linked hyaluronic acid (Electri and XELA REDERM) improve the aesthetic appearance of facial skin in adult women.
- Conditions
- Appearance of Facial Wrinkles, Aesthetic, Hydration, Facial Skin Wrinkles
- Trial name
- RegHyal-01 (NCT06984432)
- Testing
- XELA REDERM (non-cross-linked hyaluronic acid 1.1%, 1.8%, or 2.2%), Electri (non-cross-linked hyaluronic acid 0.55%)
- Where
- 4 sites in Poland, Ukraine
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Institute Hyalual GmbH
Plasma Concentrations
Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab
Determine the plasma concentration profile after single and multiple dosing of Sufentanil NanoTabs
- Trial name
- NCT01761565
- Testing
- Single dose of SUF NT 15 mcg, 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Talphera, Inc
Asperger's Syndrome, Dyslexia
My Scrivener® - Measuring Effectiveness and Dose Response in Children
This study will assess whether a computer haptic peripheral device programmed to provide repetitive motion training is as effective as the same repetitive motion training provided by a human being.
- Conditions
- Asperger's Syndrome, Dyslexia, Cerebral Palsy, Attention Deficit Disorder
- Trial name
- NCT00919906
- Testing
- My Scrivener(R)
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Obslap Research LLC
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused.
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Trial name
- NCT00248092
- Testing
- NRP104
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- New River Pharmaceuticals
Healthy
Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects
The purpose of this study is to establish the single and multiple-dose pharmacokinetics (PK) of sublingual administration of the Sufentanil Sublingual Microtablet (SSM) 30 mcg and compare the pharmacokinetics of a single dose of…
- Trial name
- NCT02082236
- Testing
- Treatment Arm A: Sufenta®, Treatment B: Sufentanil SSM 30 mcg, Treatment C: SSM 15 mcg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Talphera, Inc
Mental Disorders
Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD
This study will evaluate clinical efficacy and safety of treatment with YY-162 in children with ADHD
- Trial name
- yuyu (NCT01201187)
- Testing
- YY-162
- Where
- 3 sites in South Korea
- Volunteers
- 144 people
- Sponsor
- Yuyu Pharma, Inc.
Parkinson's Disease
A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients
This study evaluates the continuous addition of entacapone to infused levodopa and carbidopa on the pharmacokinetic (PK) profile in patients with advanced Parkinson's disease (PD). All patients will receive both study drugs, i.e.
- Trial name
- NCT02448914
- Testing
- TRIGEL, Duodopa
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- LobSor Pharmaceuticals AB
Attention Deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
This trial will evaluate the pharmacokinetics, safety, and tolerability of centanafadine in pediatric subjects with ADHD.
- Trial name
- NCT04398225
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dry Eye Disease
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
To investigate the safety and efficacy of DE-101 to improve the signs and symptoms in dry-eye disease.
- Trial name
- NCT01468168
- Testing
- DE-101 Ophthalmic Suspension, DE-101 Ophthalmic Suspension Vehicle
- Where
- 13 sites in United States
- Volunteers
- 183 people
- Sponsor
- Santen Inc.
Attention Deficit Disorder With Hyperactivity
A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the effectiveness and safety of methylphenidate HCl extended-release tablets at five dose levels compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT00326391
- Testing
- methylphenidate hydrochloride extended-release tablets
- Volunteers
- 229 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01244490
- Testing
- Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride
- Where
- 66 sites in United States, Austria and 11 more
- Volunteers
- 338 people
- Sponsor
- Shire
ADHD
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
- Trial name
- NCT00501293
- Testing
- Methylphenidate Transdermal System
- Where
- 32 sites in United States
- Volunteers
- 163 people
- Sponsor
- Noven Therapeutics
Skin Infections, Bacterial
Retapamulin Microdialysis Feasibility Study
This feasibility study will allow for the determination of the in vivo recovery and time of dialysis to optimize a future thorough microdialysis study.
- Trial name
- NCT01812382
- Testing
- Retapamulin Microdialysis
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention Deficit Hyperactivity Disorder
Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)
Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period.
- Trial name
- NCT01472991
- Testing
- TC-5619-238 5mg, TC-5619-238 25mg
- Where
- 14 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.